Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Blumenschein Jr, George
124  Ergebnisse:
Personensuche X
?
1

A Phase 1b/2 Study of Alpelisib in Combination with Cetuxim..:

Razak, Albiruni R. Abdul ; Wang, Hung-Ming ; Chang, Jang-Yang...
Targeted Oncology.  18 (2023)  6 - p. 853-868 , 2023
Link: https://doi.org/10.1007/..
 
?
2

Neoadjuvant chemotherapy plus nivolumab with or without ipi..:

Cascone, Tina ; Leung, Cheuk H. ; Weissferdt, Annikka...
Nature Medicine.  29 (2023)  3 - p. 593-604 , 2023
Link: https://doi.org/10.1038/..
 
?
3

Long-term Outcomes with Nivolumab as First-line Treatment i..:

Gillison, Maura L ; Blumenschein Jr, George ; Fayette, Jerome...
The Oncologist.  27 (2022)  2 - p. e194-e198 , 2022
Link: https://doi.org/10.1093/..
 
?
4

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy..:

Elamin, Yasir Y. ; Robichaux, Jacqulyne P. ; Carter, Brett W....
Cancer Cell.  40 (2022)  7 - p. 754-767.e6 , 2022
Link: https://doi.org/10.1016/..
 
?
5

Neoadjuvant nivolumab or nivolumab plus ipilimumab in opera..:

Cascone, Tina ; William Jr, William N. ; Weissferdt, Annikka...
Nature Medicine.  27 (2021)  3 - p. 504-514 , 2021
Link: https://doi.org/10.1038/..
 
?
6

Chimeric Antigen Receptor Therapy: How Are We Driving in So..:

Greenbaum, Uri ; Yalniz, Fevzi F. ; Srour, Samer A....
Biology of Blood and Marrow Transplantation.  26 (2020)  10 - p. 1759-1769 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined wi..:

Ramanathan, Ramesh K. ; Von Hoff, Daniel D. ; Eskens, Ferry...
Targeted Oncology.  15 (2020)  2 - p. 163-174 , 2020
Link: https://doi.org/10.1007/..
 
?
8

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanli..:

Ramanathan, Ramesh K. ; Von Hoff, Daniel D. ; Eskens, Ferry...
Targeted Oncology.  15 (2020)  6 - p. 803-803 , 2020
Link: https://doi.org/10.1007/..
 
?
9

Nivolumab treatment beyond RECIST‐defined progression in re..:

Haddad, Robert ; Concha‐Benavente, Fernando ; Blumenschein Jr, George...
Cancer.  125 (2019)  18 - p. 3208-3218 , 2019
Link: https://doi.org/10.1002/..
 
?
10

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-..:

Munster, Pamela ; Mita, Monica ; Mahipal, Amit...
Cancer Management and Research.  11 (2019)  - p. 10463-10476 , 2019
Link: https://doi.org/10.2147/..
 
?
11

Nivolumab versus investigator's choice in patients with rec..:

Saba, Nabil F. ; Blumenschein Jr., George ; Guigay, Joel...
Oral Oncology.  96 (2019)  - p. 7-14 , 2019
Link: https://doi.org/10.1016/..
 
?
12

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivol..:

Gillison, Maura L. ; Blumenschein Jr., George ; Fayette, Jerome...
The Oncologist.  23 (2018)  9 - p. 1079-1082 , 2018
Link: https://doi.org/10.1634/..
 
?
13

Nivolumab vs investigator's choice in recurrent or metastat..:

Ferris, Robert L. ; Blumenschein Jr., George ; Fayette, Jerome...
Oral Oncology.  81 (2018)  - p. 45-51 , 2018
Link: https://doi.org/10.1016/..
 
?
14

A phase I open-label dose-escalation study of the anti-HER3..:

Reynolds, Kerry Lynn ; Bedard, Philippe L. ; Lee, Se-Hoon...
BMC Cancer.  17 (2017)  1 - p. , 2017
Link: https://doi.org/10.1186/..
 
?
15

Phase II trial of single-agent foretinib (GSK1363089) in pa..:

Seiwert, Tanguy ; Sarantopoulos, John ; Kallender, Howard...
Investigational New Drugs.  31 (2012)  2 - p. 417-424 , 2012
Link: https://doi.org/10.1007/..
 
1-15